http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
부인암 환자에서 capecitabine의 효용성과 안정성
유항조,김용만,이신화,김대연,서대식,김종혁,김영탁,남주현,목정은 대한부인종양학회 2007 Journal of Gynecologic Oncology Vol.18 No.4
Objective:To determine the efficacy and safety of capecitabine in patients with gynecologic cancers as adjuvant chemotherapy or maintenance treatment. Methods:In this study, patients who were treated with capecitabine between January 2000 and June 2007 at Asan Medical Center, Seoul, Korea were reviewed. Thirty-one patients with gynecologic cancers were included 16 patients with recurrent ovarian cancer, 9 patients with cervical cancer after initial treatment, and 6 patients with recurrent cervical cancer. These patients’ data were analyzed by review of medical records and pathologic and laboratory reports retrospectively. Response was assessed by both RECIST criteria for patients with measurable disease and CA 125 criteria in patients with ovarian cancer and National Cancer Institute criteria for progression, response, and toxicity were utilized in cervical cancer. Results:Capcitabine was given at a dosage of 2,000-2,500 mg/m2/day orally in a divided dose daily for 14 days followed by a 7-day rest period in all patients. Nine patients with ovarian cancer were treated with more than 2 cycles and their median age was 49 years (43-67). Two patients showed a partial response and the median progression free survival was 3 months. Nine patients with cervical cancer after initial treatment were in the complete response state and their median progression free survival was 24.5 months. No partial or complete responses were seen in 6 patients with recurrent cervical cancer. There was no severe toxicity. Conclusion:Although capecitabine is a well-tolerated regimen, as a single agent, it produces minimal benefit in recurrent ovarian and cervical cancer population. 목적:이 연구의 목적은 부인암 영역에서 보조적 항암화학요법 또는 유지요법으로서 capecitabine의 효능성과 안정을 밝히는 것이다. 연구 방법:2000년 1월부터 2007년 6월 사이에 서울아산병원에서 capecitabine으로 치료를 받은 환자들을 대상으로 하였다. 총 31명의 부인암 환자들이 있었으며, 이 가운데 재발성 난소암 환자가 16명, 일차치료 후 유지요법을 시행받은 자궁경부암 환자가 9명, 그리고 재발성 자궁경부암 환자가 6명이었다. 이들 각 환자들의 의무기록과 병리 및 진단 검사 보고서를 통하여 분석하였다. 치료에 대한 반응은 측정 가능한 재발성 종괴가 있는 경우에는 RECIST (Response Evaluation Criteria in Solid Tumors) 기준을 적용하였고 측정 가능한 재발성 종괴가 없는 난소암의 경우에는CA 125 기준을 적용하였다. 한편, 자궁경부암에서 병의 진행, 반응성 및 독성에 대한 평가는 미국 NCI (National Cancer Institute)의 기준에 따라 진행하였다. 결과:모든 환자에서 2,000-2,500 mg/m2/day의 capecitabine을 14일간 하루 2회로 나누어 경구 투여하였다. 2회 이상의 capecitabine 치료를 시행받은 9명의 재발성 난소암 환자들의 나이는 43세에서 67세이었다. 이중 2명에서 부분관해를 나타내었으며 무병 생존기간의 중앙값은 3개월이었다. 일차치료 후 유지요법으로 capecitabine을 투여한 9명의 자궁경부암 환자에서는 모두 완전관해 상태를 유지하였으며 무병 생존기간의 중앙값은 24.5개월이었다. 재발성 자궁경부암 6명의 환자에서는 반응을 보인 경우가 전혀 없었다. 이들 모두에서 심각한 결과를 초래하는 독성반응은 보고되지 않았다. 결론:Capecitabine은 비록 안전하게 사용할 수 있는 항암화학약제이기는 하지만 재발성 난소암과 자궁경부암 환자들에게 단일제제로서의 효과는 제한적이다.
요로감염이 의심되는 환자의 소변검체에서 분리된 Escherichia Coli O26의 임상적 의의
유항조 ( Hang Jo Yoo ),주원덕 ( Won Duk Joo ),김미령 ( Mi Ryung Kim ),이수정 ( Soo Jeong Lee ),구본상 ( Bon Sang Koo ),정윤성 ( Joseph Jeong ),이선호 ( Seon Ho Lee ),김성률 ( Sung Ryul Kim ) 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.9
Objective: Escherichia coli (E. coli) O26 has been the most common type of non-O157 human isolates and it has been related with urinary tract infection and its sequelae. So we investigated the clinical significance of E. coli O26 among the cases of urinary tract infection. Methods: From January, 2005 to December, 2007, the 22 E. coli isolates that were related with urinary tract infection were analyzed. The isolates were identified biochemically by Vitek 1. We performed antisera test by O157, O26, O111 diagnostic antisera about the 22 E. coli isolates. We reviewed clinical history of the same patients retrospectively. Results: 331 E. coli isolates in the urine specimen were isolated from January, 2005 to December, 2007. 175 E. coli isolates that were related with urinary tract infection were analyzed by O157, O26, O111 antisera test. As a result, 22 isolates (13.5%) were O26 antisera positive. There were 8, 3, and 2 cases of watery diarrhea, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura repectively. Conclusion: In our study, because E. coli O26 was pathogenic and developed major complications, we concluded that patients with urinary tract infection with E. coli. should examine the antisera test about E. coli O157 and O26.
재발성 상피성 난소암 및 원발성 복막 암종증 환자에서의 Topotecan/Platinum 복합요법의 효용성과 독성
유항조 ( Hang Jo You ),김용만 ( Yong Man Kim ),이신화 ( Shin Wha Lee ),이정남 ( Jung Nam Lee ),김대연 ( Dae Yeon Kim ),서대식 ( Dae Shik Suh ),김종혁 ( Jong Hyeok Kim ),김영탁 ( Young Tak Kim ),남주현 ( Joo Hyun Nam ),목정은 ( Jun 대한산부인과학회 2008 Obstetrics & Gynecology Science Vol.51 No.1
Objective: The aim of this study was to evaluate the efficacy and toxicity of topotecan, camptothecin analogue topoisomerase I inhibitor, as the combination therapy with platinum in patients with recurrent epithelial ovarian carcinoma and primary peritoneal carcinomatosis. Method: In this study, patients who were treated with topotecan between January 2000 and June 2007 at Asan Medical Center, Seoul, Korea were reviewed. Fifty-one patients with recurrent ovarian carcinoma and peritoneal carcinomatosis were included. These patients` data were analyzed by review of medical records and pathologic and laboratory reports retrospectively. Response was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with measurable disease and CA-125 response criteria for patients with non-measurable disease. The toxicities were evaluated according to NCI CTC (Common Toxicity Criteria) version 3.0. Results: The mean age of patients was 53.4 years (ranged between 37 and 69). Forty-four patients had been evaluated by RECIST criteria. The overall response rate was 22.8% (10/44). Platinum-sensitive patients showed more favorable response rate (26.9%) than platinum-resistant patients (16.7%), however, it was not significant statistically (p=0.425). Platinum-sensitive group had significantly longer response duration (12.14 vs. 3.33 months, p=0.022) and time-to-progression (11.34 vs. 7.33 months, p=0.042) than platinum-resistant group. Heavily pretreated group, three or more prior regimens were used, had no significant differences from another group. The most common adverse effect of topotecan in combination with platinum was hematologic toxicity; grade 3/4 neutropenia was 30.6%, anemia was 42.7%, and thrombocytopenia was 8.37% in total 265 cycles of chemotherapy, however, it was tolerable. Conclusion: Topotecan in combination with platinum is considered as effective regimen with acceptable toxicity in treating recurrent epithelial ovarian carcinoma and primary peritoneal carcinomatosis who have failed previous treatment with platinum-containing chemotherapy.